These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 27391928)

  • 21. Hepatocellular carcinomas expressing 'stemness'-related markers: clinicopathological characteristics.
    Kim H; Park YN
    Dig Dis; 2014; 32(6):778-85. PubMed ID: 25376296
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical expression and localization of somatostatin receptor subtypes in prostate cancer with neuroendocrine differentiation.
    Morichetti D; Mazzucchelli R; Santinelli A; Stramazzotti D; Lopez-Beltran A; Scarpelli M; Bono AV; Cheng L; Montironi R
    Int J Immunopathol Pharmacol; 2010; 23(2):511-22. PubMed ID: 20646346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
    Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
    Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic significance of neuroendocrine markers and somatostatin receptor 2 in hepatocellular carcinoma.
    Murakami K; Kumata H; Miyagi S; Kamei T; Sasano H
    Pathol Int; 2021 Oct; 71(10):682-691. PubMed ID: 34320691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ALDH1A1-overexpressing cells are differentiated cells but not cancer stem or progenitor cells in human hepatocellular carcinoma.
    Tanaka K; Tomita H; Hisamatsu K; Nakashima T; Hatano Y; Sasaki Y; Osada S; Tanaka T; Miyazaki T; Yoshida K; Hara A
    Oncotarget; 2015 Sep; 6(28):24722-32. PubMed ID: 26160842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinicopathological significance of BUBR1 overexpression in hepatocellular carcinoma.
    Liu AW; Cai J; Zhao XL; Xu AM; Fu HQ; Nian H; Zhang SH
    J Clin Pathol; 2009 Nov; 62(11):1003-8. PubMed ID: 19861558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer.
    Sinisi AA; Bellastella A; Prezioso D; Nicchio MR; Lotti T; Salvatore M; Pasquali D
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2566-9. PubMed ID: 9253335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Octreotide inhibits proliferation and induces apoptosis of hepatocellular carcinoma cells.
    Liu HL; Huo L; Wang L
    Acta Pharmacol Sin; 2004 Oct; 25(10):1380-6. PubMed ID: 15456543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NEK2 serves as a prognostic biomarker for hepatocellular carcinoma.
    Li G; Zhong Y; Shen Q; Zhou Y; Deng X; Li C; Chen J; Zhou Y; He M
    Int J Oncol; 2017 Feb; 50(2):405-413. PubMed ID: 28101574
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors.
    Kubota A; Yamada Y; Kagimoto S; Shimatsu A; Imamura M; Tsuda K; Imura H; Seino S; Seino Y
    J Clin Invest; 1994 Mar; 93(3):1321-5. PubMed ID: 8132773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression profiles of somatostatin, dopamine, and estrogen receptors in pituitary adenomas determined by means of synthetic multilocus calibrators.
    Drastikova M; Beranek M; Gabalec F; Netuka D; Masopust V; Cesak T; Marek J; Palicka V; Cap J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Jun; 160(2):238-43. PubMed ID: 26607296
    [TBL] [Abstract][Full Text] [Related]  

  • 32. H2.0-like homeobox 1 acts as a tumor suppressor in hepatocellular carcinoma.
    Liu T; Chen J; Xiao S; Lei X
    Tumour Biol; 2016 May; 37(5):6419-28. PubMed ID: 26631039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of FOXJ1 in hepatocellular carcinoma: correlation with patients' prognosis and tumor cell proliferation.
    Chen HW; Huang XD; Li HC; He S; Ni RZ; Chen CH; Peng C; Wu G; Wang GH; Wang YY; Zhao YH; Zhang YX; Shen AG; Wang HM
    Mol Carcinog; 2013 Aug; 52(8):647-59. PubMed ID: 22488567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.
    Chen D; Xing W; Hong J; Wang M; Huang Y; Zhu C; Yuan Y; Zeng W
    Ann Surg Oncol; 2012 Oct; 19(11):3556-65. PubMed ID: 22588469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications.
    Wu PC; Fang JW; Lau VK; Lai CL; Lo CK; Lau JY
    Am J Pathol; 1996 Oct; 149(4):1167-75. PubMed ID: 8863666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Granulin-epithelin precursor overexpression promotes growth and invasion of hepatocellular carcinoma.
    Cheung ST; Wong SY; Leung KL; Chen X; So S; Ng IO; Fan ST
    Clin Cancer Res; 2004 Nov; 10(22):7629-36. PubMed ID: 15569995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Somatostatin receptors 3, 4 and 5 play important roles in gallbladder cancer.
    Guo RS; Shi PD; Zhou J; Chen YY
    Asian Pac J Cancer Prev; 2013; 14(7):4071-5. PubMed ID: 23991955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis.
    Papotti M; Bongiovanni M; Volante M; Allìa E; Landolfi S; Helboe L; Schindler M; Cole SL; Bussolati G
    Virchows Arch; 2002 May; 440(5):461-75. PubMed ID: 12021920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma.
    Hua YP; Yin XY; Peng BG; Li SQ; Lai JM; Liang HZ; Liang LJ
    Chemotherapy; 2009; 55(5):312-20. PubMed ID: 19590186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ITPKA expression is a novel prognostic factor in hepatocellular carcinoma.
    Li J; Zhu YH; Huang P; Zhang B; Sun J; Guan XY
    Diagn Pathol; 2015 Aug; 10():136. PubMed ID: 26249031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.